255 related articles for article (PubMed ID: 22211659)
1. Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
Ortu M; Vitiello P; Adorni F; Rossotti R; Di Vincenzo P; Vigano O; Galli M; Rusconi S
Curr HIV Res; 2011 Dec; 9(8):625-9. PubMed ID: 22211659
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
4. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
5. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
6. Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
Soldi GFR; Ribeiro IC; Ahagon CM; Coelho LPO; Cabral GB; Lopes GISL; Ferreira JLP; Brígido LFM;
PLoS One; 2019; 14(10):e0223210. PubMed ID: 31574109
[TBL] [Abstract][Full Text] [Related]
7. Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection.
Anderson JA; Jiang H; Ding X; Petch L; Journigan T; Fiscus SA; Haubrich R; Katzenstein D; Swanstrom R; Gulick RM;
AIDS Res Hum Retroviruses; 2008 May; 24(5):685-94. PubMed ID: 18462083
[TBL] [Abstract][Full Text] [Related]
8. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
9. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Defo VF; Moudourou S; Fokam J; Kouanfack C; Torimiro J
J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
Yalçınkaya T; Köse S
Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials.
Pichenot M; Deuffic-Burban S; Cuzin L; Yazdanpanah Y
HIV Med; 2012 Mar; 13(3):148-55. PubMed ID: 22107456
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
[TBL] [Abstract][Full Text] [Related]
13. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
[TBL] [Abstract][Full Text] [Related]
14. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
17. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.
Saracino A; Monno L; Tartaglia A; Tinelli C; Seminari E; Maggiolo F; Bonora S; Rusconi S; Micheli V; Lo Caputo S; Lazzaroni L; Ferrara S; Ladisa N; Nasta P; Parruti G; Bellagamba R; Forbici F; Angarano G
Curr HIV Res; 2009 Jul; 7(4):425-33. PubMed ID: 19601778
[TBL] [Abstract][Full Text] [Related]
19. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
20. High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.
Vidal JE; Song AT; Matos ML; Bartmann D; Anjos GD; Miranda ÉJ; Freitas ÂC; Dalben Mde F; Santana C; Segurado AC; Barreto CC; Hernández AV
Braz J Infect Dis; 2013; 17(1):41-7. PubMed ID: 23294644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
